ZTEK Stock Chart & Stats
$0.69
-$0.05(-4.63%)
At close: 4:00 PM EST
$0.69
-$0.05(-4.63%)
Day’s Range― - ―
52-Week Range$0.37 - $1.24
Previous CloseN/A
Volume66.53K
Average Volume (3M)63.87K
Market Cap
$60.40M
Enterprise Value$66.78M
Total Cash (Recent Filing)$1.30M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue402.16
Enterprise Value/Gross Profit-15.96
Enterprise Value/Ebitda-6.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance Enabling CommercializationHealth Canada clearance for ZenGUARD is a durable de-risking milestone: it validates the product for Canadian deployment, unlocks an immediate order pipeline, and materially improves the firm's ability to convert R&D into recurring sales and distribution deals over the coming months.
Modest Leverage / Conservative Balance SheetLow debt relative to equity reduces solvency risk and interest burden, providing structural financial flexibility. This lowers near-term refinancing pressure, gives management runway to pursue commercialization or strategic partnerships, and supports stability while revenues scale.
Diversified Commercialization StrategyA multi-channel approach (direct sales, licensing, partnerships) is structurally positive: licensing can scale revenue with low capex, partnerships broaden distribution and validation, and direct sales preserve margins—together reducing single-channel dependency over time.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow is a structural constraint: it necessitates external funding or dilution, limits reinvestment in commercialization and scaling, and raises execution risk if product revenues don't quickly convert to sustained positive cash generation.
Volatile And Collapsing RevenueSevere revenue volatility and an ~82% drop in 2026 indicate commercialization is not yet stable. This undermines predictable funding, weakens margin sustainability, complicates partner/customer retention, and increases the odds management must prioritize cash preservation over growth initiatives.
Recurring Losses And Equity ErosionPersistent net losses have materially eroded shareholder equity, reducing financial resilience. Continued negative returns on capital raise dilution and funding risk, constrain strategic options, and imply the company must achieve commercial traction or secure external capital to avoid further capital-base deterioration.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.37 and its highest was $1.24 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $60.40M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Aug 19, 2026 which is in 34 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Jun 25, 2026. The company reported -$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.024%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 154.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $494.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
-61.26%
Trailing 12-Months
Asset Growth
-15.42%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
1.54% Insiders
0.04% Mutual Funds
0.86% Other Institutional Investors
97.55% Public Companies and
Individual Investors